ArticleInternational journal of breast cancer2026
Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.
Article in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.International journal of breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trastuzumab emtansine (T-DM1) represents an advancement in HER2-targeted therapy, offering a unique combination of trastuzumab's specificity and the cytotoxic potency of maytansine. It demonstrates therapeutic efficacy across the spectrum of breast cancer, including both early-stage and advanced disease. With the emergence of biosimilar formulations, there is a growing need to generate real-world evidence supporting their clinical performance. This study investigates the effectiveness and safety of a T-DM1 biosimilar in routine oncology practice across adjuvant and metastatic HER2-positive breast cancer populations. Methods: In this prospective, single-institute study conducted at a tertiary oncology center in India, 116 patients with HER2-positive breast cancer (51 adjuvant and 65 metastatic) received T-DM1 biosimilar (Ujvira) between June 2021 and October 2023. Outcomes assessed included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-emergent adverse events (AEs), graded using CTCAE v5.0. Results: In the metastatic cohort, ORR was 63.4%, median PFS was 8.0 months (95% CI: 5.8-10.2), and estimated median OS was 18.0 months (95% CI: 16.1-19.9). Clinical benefit rate was 75%. In the adjuvant cohort, 62.7% completed the planned 14 cycles, and treatment was well tolerated. Grade ≥ 3 AEs occurred in 6.9% of all patients, with fatigue and thrombocytopenia being the most common AEs. No unexpected safety signals were observed. Conclusion: T-DM1 biosimilar showed outcomes consistent with those reported for the originator in real-world settings, supporting its broader adoption in both early and advanced HER2-positive breast cancer. Its affordability may improve access and outcomes in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.